People with metastatic kidney cancer who orally took a live biotherapeutic product called CBM588 while in treatment with immunotherapy and enzymatic tyrosine kinase inhibitors experienced improved health outcomes, according to research from City of Hope.
Knowledge is power, and this information, true for many cancers, is valuable for everyone to know—either to have an awareness of their own bodies and the factors that they can control, or to create spaces for empathy with persons they might encounter with cancer.
